scholarly journals The diagnostics significance of serum cancer antigen-125 in abdominal tuberculosis

2018 ◽  
Vol 5 (2) ◽  
pp. 474 ◽  
Author(s):  
Anil Kumar ◽  
Shiv S. Paswan ◽  
Bindey Kumar ◽  
Pragati Raj ◽  
. Sunita
Keyword(s):  
Disease Activity ◽  
Abdominal Tuberculosis ◽  
Serum Levels ◽  
Serum Markers ◽  
Ca 125 ◽  
Control Group ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Serial Measurement

Background: Various serum markers have been shown to be helpful in diagnosing tubercular infection, but none has been proven to be specific. The present study was undertaken to ascertain the role of serum cancer antigen (CA) -125 in diagnosing and monitoring therapeutic response in abdominal tuberculosis.Methods: Fifty diagnosed cases of abdominal tuberculosis and equal number of controls were included in the study. All the patients underwent clinical, radiological and hematological examination. Twenty-two patients had acute presentation and underwent laparotomy and twenty-eight patients had a chronic presentation and were managed conservatively. Biopsy was taken in all patients undergoing laparotomy. Serial measurement of serum levels of CA-125 were done at 0, 3 and 6 months in all the patients.Results: The CA-125 levels were significantly higher in tuberculosis patients than in control group (PPV 95.74% at 0 month). It was also observed that the levels correlated significantly with the disease activity (sensitivity 90 percent, specificity 96 percent) and return to normal level with the treatment given. It was shown that sensitivity reduced to 12 percent and 6 percent at 3 months and 6 months respectively after completion of treatment. The specificity however remained unchanged.Conclusions: The measurement of CA-125 may be a valuable parameter in diagnosing and determination of disease activity in abdominal tuberculosis.

scholarly journals Immunohistochemical Study of CA 125 in Surface Epithelial Tumors of Ovary in Correlation with Serum Levels

2020 ◽  
Vol 7 (7) ◽  
pp. A355-360
Author(s):  
Karishma Pillarisetty ◽  
Savithri Ravindra
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Neoplasms ◽  
Serum Levels ◽  
Tissue Expression ◽  
Epithelial Differentiation ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Epithelial Tumors ◽  
Wide Range

Background: Ovarian carcinoma is the 4th leading cancer among women in India. Primary ovarian neoplasms exhibit a wide range of histopathological patterns and tumors with epithelial differentiation are most frequent. Among malignant tumors, most common histological type is serous adenocarcinoma whose diagnosis is established in advanced stages of disease in approximately 75% of patients. The most widely used tumor marker in ovarian cancer, often considered “gold standard” is Cancer Antigen125. Cancer Antigen 125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with advanced epithelial ovarian cancer.   Methods: A 2 year prospective study included 81 cases of ovarian neoplasms with surface epithelial differentiation.  The specimens were fixed in 10% formalin, routinely processed. Sections of 4-5 microns thickness were obtained from the paraffin block and stained with Hematoxylin & Eosin. The tumors were categorised according to WHO classification.  Immunohistochemical analysis of Cancer Antigen 125 was done in all malignant & borderline tumors.   Result: A total of 81 cases were studied. There were 15 cases with elevated serum Cancer Antigen 125 levels. Of these 8 showed positive tissue expression. The sensitivity of serum Cancer Antigen 125 was 68.75% & its specificity was 93.8%.   Conclusion: Serum Cancer Antigen 125 is elevated in ovarian tumors especially in malignant surface epithelial tumors & more commonly in serous cystadenocarcinoma. There was a good correlation between serum levels & tissue expression of Cancer Antigen 125.

CA 125 and TB

2021 ◽  
Vol 14 (1) ◽  
pp. e238199
Author(s):  
Mirae Park ◽  
Ranju Dhawan ◽  
Elizabeth Whittaker ◽  
Onn Min Kon
Keyword(s):  
Extrapulmonary Tuberculosis ◽  
Abdominal Tuberculosis ◽  
Needle Aspiration ◽  
Tumour Marker ◽  
Endobronchial Ultrasound ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Transbronchial Needle Aspiration ◽  
Specific Symptoms

We present two unusual presentations of extrapulmonary tuberculosis (EPTB) and more specifically intra-abdominal tuberculosis (TB). These cases were initially suspicious for ovarian cancer, presenting with non-specific symptoms, ultrasound-confirmed ascites and elevated cancer antigen 125 tumour marker (CA 125). However, in both cases chest imaging demonstrated enlarged mediastinal nodes amenable to endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), which confirmed the diagnosis of TB. Both cases were successfully treated with quadruple TB therapy.

scholarly journals Luminoimmunometric Assay of Tissue Polypeptide Antigen (Tpa) and Cancer Antigen 125 (Ca-125) in Breast Cancer Patients

1993 ◽  
Vol 11 (2-3) ◽  
pp. 83-90
Author(s):  
O. El-Ahmady ◽  
Halim A.-B. ◽  
S. Eissa
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ca 125 ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Tissue Polypeptide Antigen ◽  
Cancer Antigen 125 ◽  
Cancer Antigen

Serum TPA and CA-125 were determined in 86 individuals (66 with breast cancer representing the different stages and grades of the disease and 20 normal healthy controls). TPA and CA-125 were estimated using the L1A reagents supplied by BYK Sangtec. TPA showed sensitivity rates of 31.8%, 42.4% and 51.5% while CA-125 showed sensitivities of 16.3%, 18.6% and 25.6% at specificity levels of 100%, 95% and 90% respectively. Combined determination of the two markers resulted in some improvement in sensitivity. For follow-up of breast cancer patients after surgery both markers were of value and showed near-identical patterns.

scholarly journals Evaluation of the Potential Diagnostic Utility of the Determination of Selected Caspases—Markers Involved in the Regulation of Apoptosis—In Patients with Ovarian Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 704
Author(s):  
Aleksandra Mielczarek-Palacz ◽  
Sylwia Jasińska ◽  
Anna Strzelec
Keyword(s):  
Ovarian Cancer ◽  
Caspase 3 ◽  
Serum Levels ◽  
Serous Cystadenoma ◽  
Ca 125 ◽  
Control Group ◽  
Caspase 8 ◽  
Caspase 9 ◽  
Therapeutic Problem

Ovarian cancer remains a major diagnostic and therapeutic problem in modern gynecological oncology. For this reason, research which focuses on the search for new diagnostic markers and the assessment of their possible usefulness in clinical practice is still being conducted. The aim of this study was to evaluate serum levels of caspase-3, caspase-8, and caspase-9 in women with ovarian cancer. Patients with ovarian serous cystadenoma (Cystadenoma serosum) and papillary serous cystadenocarcinoma (Cystadenocarcinoma papillare serosum IIIC) were included in the study, as well as healthy women who constituted the control group. The results of the study revealed a statistically significantly decreased mean serum levels of caspase-3, caspase-8, and caspase-9 in women with ovarian cancer as compared to the control group (p ˂ 0.001), which indicates the involvement of the studied parameters in immune system disturbances occurring in the process of apoptosis by the extrinsic and intrinsic pathway and may be one of the mechanisms of immunosuppression accompanying these tumors. Determination of serum levels of examined caspases and CA 125 antigen in women with ovarian cancer in combination with other markers may prove useful in the future in the diagnosis of ovarian cancer, but this requires further studies.

Preoperative Measurement of Cancer Antigen 125 (CA 125) in the Differential Diagnosis of Ovarian Tumors

1989 ◽  
Vol 28 (4) ◽  
pp. 471-473 ◽  
Author(s):  
O. Mogensen ◽  
B. Mogensen ◽  
A. Jakobsen ◽  
A. Sell
Keyword(s):  
Differential Diagnosis ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen

scholarly journals Pre-Treatment Prediction of Chemoresistance in Second-Line Chemotherapy of Ovarian Carcinoma: Value of Serological Tumor Marker Determination (Tetranectin, YKL-40, CASA, CA 125)

2006 ◽  
Vol 21 (3) ◽  
pp. 141-148 ◽  
Author(s):  
B. Gronlund ◽  
E.V.S. Høgdall ◽  
I.J. Christensen ◽  
J.S. Johansen ◽  
B. Nørgaard-Pedersen ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Tumor Markers ◽  
Predictive Value ◽  
Serum Levels ◽  
Ca 125 ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Serological Tumor ◽  
Line Chemotherapy

Objective To examine if the determination of the levels of serological tumor markers at time of relapse had any predictive value for chemoresistance in the second-line treatment of ovarian cancer patients. Methods From a registry of consecutive single-institution patients with epithelial ovarian carcinoma pretreated with paclitaxel plus platinum, we selected 82 patients with (a) solid tumor recurrence, and (b) second-line chemotherapy consisting of topotecan (platinum-resistant disease) or paclitaxel plus carboplatin (platinum-sensitive disease). Stored serum samples were analyzed for the biochemical tumor markers tetranectin, YKL-40, CASA (cancer-associated serum antigen), and CA 125. The serum tumor marker levels at time of relapse were correlated with response status at landmark time after 4 cycles of second-line chemotherapy. Univariate and multivariate logistic regression analyses (chemoresistant vs non-chemoresistant disease) were performed. Results At landmark time, 26% of patients had progression according to the GCIG (Gynecologic Cancer Intergroup) progression criteria. In univariate logistic regression analysis, the tumor markers tetranectin (OR 0.4; 95% CI: 0.2–0.8; p=0.008), YKL-40 (OR 1.8; 95% CI: 1.0–3.3; p=0.045), and CASA (OR 1.8; 95% CI: 1.2–2.7; p=0.007) had predictive value for second-line chemoresistance, whereas serum CA 125 had no predictive value. In a multivariate logistic regression analysis, serum tetranectin and CASA both had independent predictive value for chemoresistance. The combined determination of tetranectin and CASA had a specificity of 90% with 33% sensitivity for the prediction of chemoresistance (area under the receiver operating characteristic curve = 0.78; 95% CI: 0.66–0.91; p=0.001). Conclusion Low serum levels of tetranectin, or high serum levels of CASA or YKL-40, are associated with increased risk of second-line chemoresistance in patients with ovarian cancer.

Serum prolactin and CA 125 levels in uterine adenomyosis

2020 ◽  
Vol 12 (3-4) ◽  
pp. 165-169
Author(s):  
Ayçağ Yorganci ◽  
Nezaket Kadioğlu ◽  
Harika Gümgümcü ◽  
Şebnem Özyer ◽  
Yaprak Engin-Ustun
Keyword(s):  
Retrospective Chart Review ◽  
Thyroid Stimulating Hormone ◽  
Study Data ◽  
Ca 125 ◽  
Serum Prolactin ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Volume Group ◽  
Uterine Adenomyosis ◽  
Uterine Volume

Objective: It is suggested that prolactin has a role in the pathogenesis of uterine adenomyosis. Besides, it is also reported that elevated cancer antigen 125 levels are related with this benign disorder. The aim of the study was to investigate serum prolactin and cancer antigen 125 levels in patients with adenomyosis. Methods: In this retrospective chart review study, data of patients with clinically diagnosed and histopathologically proven adenomyosis in hysterectomy specimens were analyzed. Patients were divided into two groups according to the ultrasonographically calculated preoperative uterine volume: Group 1 (n = 62): uterine volume ⩽240 cm3 (⩽12 gestational weeks) and Group 2 (n = 42): uterine volume >240 cm3 (>12 gestational weeks). Age, obstetric history, body mass index, preoperative hemoglobin, thyroid stimulating hormone, prolactin and cancer antigen 125 levels, and ultrasonographic findings were recorded. Preoperative prolactin and cancer antigen 125 values were compared between the two groups. Results: A total of 104 patients were included in the study. No differences in the baseline characteristics were observed between the groups, except the number of pregnancies and miscarriages. Furthermore, no significant differences were observed in terms of serum prolactin and cancer antigen 125 levels between the groups. Conclusion: Serum prolactin and cancer antigen 125 levels were not associated with uterine volume in patients with uterine adenomyosis.

Diagnostic value of anti-CD74 antibodies in early and late axial spondyloarthritis and its relationship to disease activity

Rheumatology ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 263-268 ◽  
Author(s):  
Marwa Mahmoud Abdelaziz ◽  
Rania M Gamal ◽  
Nadia M Ismail ◽  
Raghda A Lafy ◽  
Helal F Hetta
Keyword(s):  
Disease Activity ◽  
Axial Spondyloarthritis ◽  
Diagnostic Value ◽  
Inactive Disease ◽  
Control Group ◽  
Igg Antibodies ◽  
Control Groups ◽  
Significant Difference ◽  
Healthy Control

Abstract Objectives This study was designed to evaluate the role of anti-CD74 antibodies in diagnosis of axial spondyloarthritis (axSpA) and their relationship to disease duration and disease activity. Methods Fifty patients with axSpA, 15 patients with RA and 15 healthy subjects were included in the study. Clinical examination and laboratory tests were done. The ESR, CRP level and ASDAS were measured as markers of the disease activity. Quantitative determination of human CD74 IgG antibodies was done. Results The mean age of the patients was 38.22 (S.D.12.20) years. The level of CD74 autoantibodies was significantly higher in axSpA in comparison to control groups. Most patients with positive articular and extra-articular manifestations were positive for CD74 autoantibodies. In patients with inactive disease, 33.3% were positive for CD74 autoantibodies, as were 83% with active disease. High percentages of patients with early and late axSPA were CD74 autoantibody positive. The majority of patients with positive disease activity in early and late axSpA were CD74 autoantibody positive. CD74 autoantibodies had 80% sensitivity vs both control groups with 87% specificity vs the healthy control group and 80% vs the RA control group in the diagnosis of axSpA. Conclusions The frequency of positive anti-CD74 IgG antibodies was as high in patients with early axSpA as in those with late axSpA, with no significant differences. There was a significant difference in the frequency of positive anti-CD74 IgG antibodies between patients with positive and negative disease activity. Based on the sensitivity and specificity of anti-CD74 IgG, this is a promising diagnostic tool to support the clinical diagnosis of axSpA.

Sign in / Sign up

Export Citation Format

Share Document